May 6 (Reuters) - Activist investor Glenview Capital

said on Tuesday it had reduced its holdings in CVS Health ( CVS )

following the insurer's "healthy" first-quarter results.

CVS shares have generated a total return of 25% since it

took a position last year, suggesting progress in the company's

turnaround plan, the hedge fund said.

Glenview previously owned nearly 12 million shares of CVS,

according to its latest regulatory filing. It reduced its

holdings by 3.75 million shares, just days after the healthcare

conglomerate raised its annual forecast and beat Wall Street

estimate for quarterly profit.

CVS had been facing pressure from investors, including

Glenview, to improve its operations and shareholder value after

missing financial targets several times due to increased medical

costs in its health insurance business.

In October, CVS replaced CEO Karen Lynch with company

veteran David Joyner and a month later added Glenview's top boss

and three others to its board.

Joyner has since laid out cost-cutting plans and reshuffled

the top management to help the company navigate one of the most

challenging periods in its six-decade history.

Glenview said it has no plans for additional adjustments to

its holdings with the company.

"Our confidence in the near, medium and long-term outlook

for CVS remains strong," the hedge fund said.

Last week, CVS raised its 2025 profit forecast to $6 to

$6.20 per share, from $5.75 to $6 projected previously. It also

reported first-quarter profit above analysts' estimate on

lower-than-expected medical costs.